We maintained strong blood stock levels through our
dedicated collection teams and everyone who supports
them, plus well-planned marketing activity.
We collected nearly 2 million blood donations from nearly
1.4 million donors from teams operating across England
and North Wales.
Blood collection productivity
increased again this year and has grown by 22% over the
past three years.
We carried out 3,740 transplants in the UK - the sixth year on year growth in
the number of transplants. And the number of deceased
organ donors increase to over 1,000 - a new record.
Consent rates for organ donation following brain death
also continued to rise from 61% of families approached
about donation in 2009/10 to 65% in 2010/11.
We delivered £30m in savings to the NHS to reinvest in
frontline patient care through a successful three-year
change programme. This saw us consolidate some of our
manufacturing and testing departments to reduce the cost
of a unit of blood from £140 in 2008/09 to just under
£125 by 2010/11.
We improved security of blood
supply, reducing the number of days where stock levels
have fallen below acceptable levels from 87 in 2007/8 to
only two in 2010/11.
We have increased
productivity in testing by 35% and in processing by 50%
since April 2008. This means we are on track to achieve
European top quartile performance levels in both areas
by the end of 2011/12.
We improved blood safety
by introducing bacterial screening and improving the way
we assess new tests.
We reduced incidences of
fainting and rebleeding which improved blood donor
safety and satisfaction.
We also reduced the
number of non-compliances from regulatory inspections.
We delivered the first UK-wide 10 year stem cell
transplant strategy to all four governments. And we have
already started implementing findings through high
resolution stem cell testing to deliver better patient
outcomes.